Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ETCompany ParticipantsBreno Toledo Pires de Oliveira - Chief ...

OKYO Pharma (OKYO) announces the filing of its application for Fast Track designation, FTD, with the U.S. Food and Drug Administration, FDA, for urcosimod for the treatment of neuropathic corneal ...

Following recommendations by the World Health Organization (WHO), the United Nations Commission on Narcotic Drugs (CND) has decided to place five new psychoactive substances and one medicine under ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

Innocan Pharma Ltd. Each Warrant is exercisable into one Common Share at a price of CAD$0.26 for a period of four (4) years from the date of issuance. Innocan intends to use the proceeds of the ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $300.00. The company’s shares closed yesterday at $245.20.

Gland Pharma Ltd on Tuesday (February 25) announced that America's drug regulatory watchdog has completed a crucial inspection of its Andhra Pradesh facility. In a regulatory filing, Gland Pharma said ...

Trump last week said he was considering new duties of around 25% on pharmaceutical products, along with automobiles and semiconductors, as early as April. The tariff rates will "go very ...

SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and ...